Several studies have documented the ability of flavonoids to sensitize cancer cells to chemotherapeutics and reverse multidrug resistance by inhibition of efflux pumps (adenosine triphosphate-binding cassette transporters), apoptosis activation, and cell cycle arrest. In this study, the flavonoid rutin (quercetin 3-O-β-D-rutinoside) was investigated as chemosensitizer towards two different human epithelial breast cancer cell lines: (i) MB-MDA-231, selected as representative for triple-negative breast cancer and (ii) MCF-7 used as a well-characterized model of HER2-negative breast cancer. To assess the cytocompatibility of rutin against non-cancer cells, primary human mammary fibroblasts were used as control and non-target cells. In MDA-MB-231 cells, 20 μM rutin enhanced cytotoxicity related to cyclophosphamide and methotrexate. Rutin significantly (p < 0.05) increased the anticancer activity of both chemotherapeutics, at 24-48-72 h, and decreased the activity of the adenosine triphosphate-binding cassette transporters, namely, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Flow cytometry analysis showed 20 μM and 50 μM rutin arrested cell cycle at G2/M and G0/G1 phases, respectively, significantly promoting cell apoptosis. Rutin, via non-selective inhibition of P-gp and BCRP pumps, efficiently reverses multidrug resistance and restores chemosensitivity to cyclophosphamide and cyclophosphamide of human chemoresistant, triple-negative breast cancer cells, successfully arresting cell cycle progression.
INTRODUCTION
Plant natural products have represented (and still represent) an almost limitless source of lead compounds for anticancer drug discovery, as witnessed by vinca alakaloids, camptothecin, taxol, and podophyllotoxin analogues, just to cite a few (Hosseini and Ghorbani, 2015) . Among phytochemicals, flavonoids, a large group of phenylalanine derivatives belonging to polyphenol class, include the subclass of flavonols, which are represented, among the others, by rutin, quercetin, and kaempferol. The latter deserve particular attention because of their anticancer activity and not only that (Iriti and Varoni, 2013) . The flavonoid basic chemical structure is the flavan nucleus, consisting of 15 carbon atoms arranged in three rings (C 6 -C 3 -C 6 ): two aromatic rings (A and B) connected by a three-carbon-atom heterocyclic ring, an oxygencontaining pyran ring (C) (Fig. S1 ) (Iriti and Varoni, 2015) .
Despite the outstanding progress, during the last few decades, the risk of tumor resistance to chemotherapy continues to represent a major hurdle in clinical oncology, because the effective dose of anticancer drug would require to be increased to a non-manageable level. Multidrug resistance (MDR) is a phenomenon in which cancer cells exhibit a cross-resistant phenotype against multiple unrelated drugs with different structure and/or function that may have diverse molecular targets. MDR represents a crucial factor in the failure of many forms of chemotherapy. Cancer cells may exhibit intrinsic (or primary) MDR or they may acquire MDR during chemotherapy (Saraswathy and Gong, 2013) . In any case, the etiology of MDR is multifactorial. A number of different mechanisms can mediate the development of MDR, including increased drug efflux from the cell by energy-dependent membrane transporters and defective apoptotic pathway (e.g. resistance to proapoptotic signals). To date, the most widely studied MDR mechanisms are those associated with drug efflux mechanisms involving adenosine triphosphate-binding cassette (ABC) transporter superfamily. In humans, more than 48 MDR genes were identified; among them, the most extensively characterized MDR membrane transporters include P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance associated protein-1 (MRP1/ ABCC1) (Saraswathy and Gong, 2013) . Recently, several studies have documented the ability of phytochemicals, including flavonoids, to increase the sensitivity of cancer cells to anticancer drugs and to reverse MDR by the inhibition of ABC transporters (Michalak and Wesolowska, 2012) . In this view, flavonoids may improve the efficacy of conventional cancer chemotherapy through additive or synergistic effects with traditional chemotherapeutics or by inducing chemosensitization in resistant cancer cells. Nonetheless, flavonoids may decrease cancer therapy-induced toxicity and they may reduce the risk of deleterious, undesirable side effects (Lecumberri et al., 2013) .
As reported, in 2012, by the International Agency for Research on Cancer of the World Health Organization, breast cancer ranked as the first most common malignancy in Europe, with an incidence of 92.8 per 100.00 women (http://eco.iarc.fr/eucan/). Studies related to breast cancer can be targeted towards different tumor subtypes that are commonly classified as follows: (i) breast cancer overexpressing estrogen receptors (ER) and/or progesterone receptors (PR); (ii) breast cancer showing human epidermal growth factor-2 (HER-2/ neu) amplification; and (iii) breast cancer that are negative for these markers named triple negative (TN). The latter subtype is of high clinical interest because it is treated with chemotherapeutic agents and radiotherapy. Differently, ER/PR and HER-2/neu positive breast cancers are treated with inhibitors targeted towards hormone-related or HER-2/neu pathways, respectively. TN breast cancer is a heterogeneous subset of malignancies that globally accounts for approximately 10-20% of diagnosed breast cancers; the lack of targeted therapies for this aggressive breast cancer subtype results in poor overall prognosis (Martin et al., 2014) . In this study, the effects of rutin (quercetin 3-O-β-D-rutinoside), as chemosensitizer, were explored against TN breast cancer cells (MDA-MB-231), ER, and PR positive breast cancer cells (MCF-7) and primary human mammary fibroblasts (HMFs). In particular, we investigated the use of rutin in combination with conventional anticancer drugs cyclophosphamide (CYC) and methotrexate (MTX). Noteworthy, after rutin addition, half-dosage chemotherapeutic administration caused the same effects in cancer cells in comparison with the therapeutic doses of CYC and MTX, though strongly reducing their dose-dependent toxicity on non-target cells. Finally, MDR reversal, apoptosis induction, and cell cycle arrest were investigated to identify the mechanisms involved in rutin-induced chemosensitization. [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl Cell culture conditions. Human breast cancer MDA-MB-231 and MC-F7 cell lines were grown according to the manufacturer's instructions. Cells were cultured in flasks of 75 cm 2 (PAA Laboratories GmbH, Austria) in EMEM media supplemented with 10% FBS and antibiotics: 100 IU mL À1 penicillin, 100 μL mL À1 streptomycin, and 0.25 μL mL À1 amphotericin B in a CO 2 incubator at 37°C and in a saturated steam atmosphere with 5% carbon dioxide (CO 2 ).
MATERIALS AND METHODS
Primary HMFs were obtained by a 30-min enzymatic digestion (1 mg mL À1 collagenase, 0.3 mg mL À1 dispase, 0.25% trypsin in PBS, at 37°C) Cochis et al., 2015) of fresh human tissues, collected from breast cancer patients. After incubation, the enzyme activities were inhibited by adding complete medium, α-MEM plus 10% heat inactivated FBS and 1% antibiotics; the solution was filtered through a 100 μm cell strainer and centrifuged for 5 min at 900 rpm. Finally, the pellet was resuspended in complete media and cells seeded at a defined concentration (5 × 10 4 cells/cm 2 ). Written informed consent of each patient was guaranteed, in full respect of the "Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects". HMFs, were cultivated in complete α-MEM until 80-90% confluency, washed carefully with PBS, detached with a trypsin-EDTA solution, and used for experiments within the second and the fourth passage.
Drug administration. Rutin, CYC, and MTX were dissolved in DMSO prior to each experiment and administrated as single drugs or in combinations, as detailed in Table S1 .
Cells (MB-MDA-231, MCF-7, and HMFs) were plated in a defined number (1 × 10 4 cells/well) into 96 wells plates using the appropriate medium and then allowed to adhere overnight. Afterwards, drugs were directly added to the cells. At 24, 48, and 72 h time points, cell viability was evaluated by the colorimetric metabolic MTT assay. Briefly, 20 μL of MTT solution (3 mg mL À1 in PBS) were spotted onto each well; plates were then incubated 4 h in the dark at 37°C. Medium was then removed and formazan crystals dissolved in 100 μL DMSO. Lastly, 50 μL aliquots were collected from each well and the optical density measured by spectrophotometer (VICTOR ® , PerkinElmer, MA, USA) at 570-nm wavelength. Cells cultivated with untreated medium were considered as controls. Accordingly, data were normalized and expressed as % of viability over controls. Experiments were performed three times in triplicate.
Calcein acetoxymethyl accumulation assay. Calcein acetoxymethyl AM ester, a fluorescent dye and substrate for P-gp efflux pump, was used to evaluate the functional activity and efflux pattern of P-gp in TN MDA-MB-231, in presence of 20 and 50 μM rutin (Singh et al., 2015) . Treatment with Verapamil hydrochloride, a well-known P-gp inhibitor, was performed as positive control for this assay. Thus, to investigate P-gp activity in presence of rutin, calcein was dissolved in DMSO at a final concentration of 5 μM and stored À20°C until use. Prior to each assay, the stock solution was diluted in the complete proper cell culture medium. To investigate P-gp activity in presence of rutin, MB-MDA-231 cells were seeded into three different black 96-well plates (1.5 × 10 4 cells/well), for each time point (24, 48, and 72 h) . Cells were allowed to attach overnight; then 20, 50 μM rutin, or 20 μM verapamil (positive control) were administered. Finally, calcein was added to a final concentration of 0.5 μM to each well (200 μL final volume), and fluorescence was recorded every 1 min up to 10 min at 530-nm wavelength, using a spectrophotometer (VICTOR ® , PerkinElmer, MA, USA), following Manufacturer's Instructions.
Rhodamine-123 uptake assay. Rhodamine 123, a fluorescent dye and substrate for both P-gp and BCRP efflux pumps, was used to further investigate functional activity and efflux pattern of BCRP, besides P-gp, in TN MDA-MB-231, in presence of 20 and 50 μM rutin (Singh et al., 2015) . Rhodamine 123 was dissolved in ethanol (100%) at a final concentration of 5 mg mL À1 , stored at À20°C, and diluted in the proper medium prior to each assay. MB-MDA-231 cells were cultivated consecutively for 72 h with 20 or 50 μM rutin, as described for calcein assay. In parallel, cells were pre-treated for 48 h with 20 μM verapamil, to block P-gp efflux pump, and then added with 10 μM KO143, for the last 24 h, in order to provide specific inhibition also to efflux pump BCRP (positive control). Then, rhodamine 123 was added at a final concentration of 1 μM to each well (200 μL total volume), and cells were incubated at 37°f or 1 h. After treatment, cells were washed twice with PBS and fluorescence was recorded by spectrophotometer (VICTOR ® , PerkinElmer, MA, USA) at 530-nm wavelength, following manufacturer's instructions. Results were expressed as relative fluorescence unit, that is, percentage of fluorescence over untreated cells (controls).
Analysis of apoptosis by flow cytometry: Annexin V and 7-aminoactinomycin D. Muse ® Annexin V and Dead Cell Assay is based on the detection of phosphatidylserine on the outer layer of plasma membrane. Externalization of phosphatidylserine at cell surface represents a typical feature of apoptosis and can be detected by Annexin V conjugated with FITC (fluorescein isothiocyanate). In addition, 7-aminoactinomycin D (7-AAD), a fluorescent DNA intercalator generally excluded from live cells, is used to stain dead cells. Both cell lines were seeded in six well plates in an amount of 5 × 10 5 cells/well and grown for 72 h to obtain a logarithmic growth. Cells were incubated in complete culture medium containing 20 and 50 μM rutin for 24 and 48 h. Then, 1 × 10 6 cells in suspension were transferred to a new tube and incubated with 100 μL of Annexin V & Muse Dead Cell reagent for 20 min at room temperature. Apoptosis was determined by Muse ® Cell Analyzer (emission max: yellowred 576 and 680 nm; excitation max: 532 nm) (Millipore, Billerica, MA). Pure medium with FBS serum was used as negative control, whereas medium with 100 nM paclitaxel, an inducer of apoptosis, was used as positive control (Saleh et al., 2015) .
Analysis of apoptosis by flow cytometry: caspase-3/7 and 7-aminoactinomycin D. Muse ® Caspase-3/7 Assay detects the activation of caspase-3/7, the main proteases involved in apoptosis. Cells were cultured as previously reported for Annexin V Assay. After incubation with 20 or 50 μM rutin for 24 and 48 h, cells were removed by Accutase ® (a cell detachment solution) and suspended in a buffer (2 × 10 5 cells mL À1 ). Then, the assay was carried out according to the manufacturer's instructions. Medium with 100 nM paclitaxel, inducer of apoptosis, was used as positive control (Carr et al., 2014) .
Flow cytometry analysis of cell cycle: propidium iodide staining. Muse ® Cell Cycle Assay was performed according to the manufacturer's instructions. Briefly, cells were plated at 1 × 10 4 cells/well and incubated in medium containing 10% FBS at 37°C. Then, cells were incubated with medium containing 20 or 50 μM rutin for 24 and 48 h. Finally, cells were washed with PBS and centrifuged; cold, freshly prepared 70% ethanol was poured, and samples were maintained at 20°C until further analysis. Afterwards, cells were washed with PBS and processed for cell cycle analysis in accordance with the manufacturer's instructions (Saleh et al., 2015) .
Statistical analysis of data. Results are expressed as means ± standard deviation (SD). Data were analyzed using SPSS Software (v20, IBM, New York, USA) and statistical software package STATISTICA (version 8.0, Statsoft). Normality of distribution was determined with Shapiro-Wilk test. One-way ANOVA followed by Sheffe's test was used in case of normal distribution of data and independent samples. Statistical differences were evaluated by non-parametric Friedman's ANOVA variance analysis followed by post hoc Conover's test or Dunn's test in case of multiple dependent comparison, and Wilcoxon's test in case of two sample comparisons. Student's T-test was used in case of two independent sample comparison. Values of p < 0.05 were considered statistically significant.
RESULTS

Rutin cytotoxicty
When used as single compound, rutin did not cause any significant decrease in cells viability in all the treated cells (MDA-MB-231, MCF-7, and HMFs), at all the assayed concentrations (20, 40, 50, and 100 μM). In TN MDA-MB-231 cells, no viability reduction was appreciable after 24 h, while after 48 and 72 h, the observed slight decrease resulted not significant in comparison with untreated controls (0.5% DMSO in complete medium). Moreover, no dose-dependent behavior was noticed, as well as no statistically significant difference was found among rutin at different concentrations tested. Very similar results were obtained by treating HER-2/neu negative MCF-7 cells; even if a more marked toxicity was observed in comparison with untreated controls (0.5% DMSO in complete medium), results were not significant after any time point tested. Moreover, as noted for MDA-MB-231 cells, no dosedependent behavior of rutin was found, as no difference in terms of toxicity was observed among increasing concentrations.
Finally, by administering rutin to primary HMFs, no toxic effect was observed at any time point, thus demonstrating that this flavonoid is highly cytocompatible, at 20-40-50-100 μM, after 24-48-72 h of cell culture.
Chemotherapeutic drugs effect against breast cancer cell lines
To verify CYC and MTX efficacy, the therapeutic dosages of 40 μM CYC and 4 μM MTX were assayed in comparison with their respective half-doses (20 μM CYC and 2 μM MTX) towards both cancer (MDA-MB-231 and MCF-7) and normal (HMFs) cells (Fig. 1) . As expected, the highest concentrations of CYC (40 μM) and MTX (4 μM) determined the highest decrease in cancer cell viability, independently from the type of cell line considered. In particular, 40 μM CYC significantly reduced cell viability of both MDA-MB-231 (Fig. 1A) and MCF-7 (Fig. 1B) , after 48-72 h, in comparison with untreated control (0.1% DMSO in complete medium) (p < 0.05, statistical significance indicated by *). On the other hand, after 48-72 h, the lower concentration of CYC (20 μM) did not significantly affected survival of MDA-MB-231 cells over controls, though it significantly reduced viability of MCF-7 (p < 0.05, indicated by *). Therefore, a dose-dependent response was observed for MDA-MB-231, at both 48 and 72 h, when the differences in cell survival between 20 μM CYC and 40 μM CYC were statistically significant (p < 0.05, indicated by #. On what concerns MTX, the higher concentration (4 μM) significantly decreased cell viability of both MDA-MB-231 and MCF-7 at all experimental time points (24-48-72 h), in comparison with the control (p < 0.05, indicated by *). After 48-72 h, 2 μM MTX significantly reduced survival of both cell lines over controls (p < 0.05, indicated by *). The statistical comparison between 4 μM MTX and 2 μM MTX demonstrated significant dose-dependent response only after 48 h, in both MDA-MB-231 and MCF-7 (p < 0.05, indicated by §).
To verify cytotoxicity, primary non-tumorigenic cells (HMFs) were used: after 48-72 h, 40 μM CYC and 4 μM MTX significantly reduced viability of HMFs by >50% (p < 0.05, indicated by *) (Fig. 1C) . Half dosages (20 μM CYC and 2 μM MTX) were also slightly toxic on these primary cells, determining a cells viability decrease of about <30%, at each time point that was not statistically significant (p > 0.05). Consistently, comparing 40 μM CYC with 20 μM CYC, and comparing 4 μM MTX with 2 μM MTX, differences in cell survival were always significant, further supporting a dose-dependent toxicity of chemotherapeutics (p < 0.05, indicated by # and §, respectively).
Rutin is an adjuvant agent
According to the data obtained from the cytotoxicity assays, the lowest rutin concentration (20 μM) was combined with the least effective concentrations of both chemotherapeutic drugs in order to evaluate the synergic efficacy of the combination against cancer cells at poorly toxic doses (see Table. S1 for summary of combined treatments and compound doses).
In ER and PR positive MCF-7 cells, although at 24 h 20 μM rutin alone did not significantly affect 20 μM CYC and 2 μM MTX cytotoxicity ( Fig. 2A) , at 48 and 72 h chemotherapeutics, in presence or not of rutin, significantly decreased cell viability ( Fig. 2B and C, respectively) (p < 0.05, indicated by *). Rutin did not further enhanced efficacies of 20 μM CYC and 2 μM MTX alone, at each time point ( Fig. 2A-C) ; thus, in terms of anticancer efficacy, no difference was observed between drugs alone and their combinations with this flavonoid.
In TN MDA-MB-231 cells, rutin alone showed significant cytotoxicity at 72 h (p < 0.05, indicated by *) in comparison with the control (0.1% DMSO in complete media), but not at 24 and 48 h (Fig. 3A-C) . 20 μM CYC alone significantly reduced cell viability of cancer cells at all experimental time points (p < 0.05, indicated by *), while 2 μM MTX was effective just after 48 and 72 h of treatment (Fig. 3A-C) . The combinations of 20 μM rutin with the two chemotherapeutics (20 μM rutin + 20 μM CYC and 20 μM rutin + 2 μM MTX) significantly reduced cell viability versus control after 24-48-72 h (Fig. 3A-C) (p < 0.05, indicated by *). Noteworthy, 20 μM rutin significantly increased 20 μM CYC and 2 μM MTX cytotoxicity at all experimental time points (Fig. 4A-C) (p < 0.05, indicated by # for CYC and § for MTX). The anticancer activity of 2 μM MTX alone was not significant after 24 h (p > 0.05), while the addition of the flavonoid (20 μM rutin + 2 μM MTX) increased the anticancer activity of 2 μM MTX to significant level (Fig. 3A) (indicated by #).
Rutin counteracted the activity of efflux pumps
In order to explore the mechanisms involved in the activity of rutin as adjuvant anticancer agent in combination with chemotherapeutics, the effects of this flavonoid on the efflux pumps of TN MDA-MB-231 Resulting effects were compared with Verapamil, inhibitor of P-gp, and Ko143, inhibitor of both P-gp and BCRP (Fig. 4) .
Rutin showed similar inhibitory effect on P-gp and BCRP efflux pumps as the inhibitors used as positive controls, that is, verapamil and Ko143. At fluorescence analyses of calcein AM (specific substrate of P-gp efflux pump, thus marker of its functionality), results revealed that, after 24 h of incubation with 20 μM rutin, 50 μM rutin, or 20 μM Verapamil, a statistically not significant difference among treatments could be observed (Fig. 4A) . Similar trends were observed for calcein assay after 48 (Fig. 4B ) and 72 h (Fig. 4C) . At fluorescence analyses of rhodamine 123 (specific substrate of P-gp efflux pump, thus marker of its functionality), at 72 h, the positive control, that is, 10 μM Ko143 in combination with 20 μM verapamil, was still not significantly different from the treatments with 20, 50 μM rutin (p > 0.05) (Fig. 4D) .
Apoptosis detection after rutin treatment
After exposure to 20 and 50 μM rutin, MDA-MB-231 and MCF-7 cells were stained with Annexin V and 7-AAD; the former marker of phosphatidylserine externalization at cell surface, typical feature of apoptosis, and the latter DNA intercalator in dead cells. Cells were, then, analyzed by flow cytometry to assess the percentage of apoptotic and necrotic cells. Following 24 h of incubation, a slight increase in apoptotic cell phenotype (Annexin+/7-AAD+ and Annexin+/7-AADÀ) was observed in both cancer cell lines, compared with the control group, but without statistical significance ( Fig. 5A and B) . The most noticeable changes were detected after 48 h of incubation with 50 μM rutin in MDA-MB-231. In this case, the number dead cells (AnnexinÀ/7-AAD+) significantly increased over untreated controls (p < 0.05, indicated by *) (Fig. 5B) .
To verify the possible activation of the apoptotic pathway, additional assays for caspase-3/7, key proteases involved in apoptosis, and 7-AAD were carried out. As a result, flow cytometric analysis demonstrated that the flavonoid slightly affected caspase activation in TN MDA-MB-231 cells, at 24 h ( Fig. 6A and B) . At 48 h, 50 μM rutin significantly increased the total pool of cells with apoptotic phenotype (Caspase-3/7 +/7-AAD+) over controls (p < 0.05, as indicated by *) (Fig. 6A and B ). Significant changes in caspase activation were observed, even at higher extent, in MCF-7 cells. After 24 and 48 h, incubation of MCF-7 cells with 20 and 50 μM rutin significantly increased the percentage of apoptotic cell phenotype (p < 0.05, as indicated by *) (Caspase-3/7+/7-AAD+) (Fig. 6) .
Cell cycle progression after rutin treatment
Considering TN MDA-MB-231, data showed as the 24-h treatment with both concentrations of rutin did not produce any change in cell cycle over controls (Fig. 7) . After 48-h incubation, instead, both 20 and 50 μM rutin significantly increased the percentage of MDA-MB-231 cells in G0/G1 (p < 0.05) and G2/M (p < 0.05) phases, respectively (Fig. 7) . Noteworthy, at this time point, MDA-MB-231 cells in S phase significantly decreased after treatment with 50 and 20 μM rutin (p < 0.05) (Fig. 7) .
The effect of 50 μM rutin in MCF-7 appeared at earlier then MDA-MB-231: after 24 h, the flavonoid significantly increased the percentage of MCF-7 cells at G0/G1 phase (p < 0.05), decreasing cells in G2/M (p < 0.05) (Fig. 7) .
DISCUSSION
Though in vitro anticancer activity of flavonoids is known since decades, as well as their in vivo chemopreventive potential, the reversal of MDR in cancer cells by these compounds has been barely investigated (Michalak and Wesolowska, 2012) . In particular, antitumor activity on TN MDA-MB-231 cells of two aglycones, namely, quercetin and kaempferol, both belonging to the flavonol group of flavonoids as rutin (a glycoside), has been previously documented (Huang et al., 2011; Rzepecka-Stojko et al., 2015) . Likewise, anti-MDR activity of these compounds has been also explored in melanoma, leukemic and erythroleukemic cell lines (Yanqiu et al., 2011; Bourogaa et al., 2011) .
In our work, we demonstrated the effects of rutin as anticancer adjuvant agent, able to increase the cytotoxicity of two conventional chemotherapeutic drugs (CYC and MTX) against MDA-MB-231 cells, model of TN breast cancer subtype, characterized by the lowest response to chemotherapies and, consequently, the worst outcome. In particular, we demonstrated that rutin, although with poor or absente efficacy (at least in our experimental conditions) against breast cancer cell lines, seems able to act in combination with the chemotherapeutics tested, increasing their efficacy. As shown in Fig. 1 , rutin (20 μM) was ineffective against MCF-7 cells both alone and in combination with CYC (20 μM) or MTX (2 μM). However, as reported in Fig. 2 , rutin (20 μM) exhibited a slight effect against MDA-MB-231 cells after 72 h (Fig. 2C) , besides increasing significantly the efficacy of MTX 2 μM, after 24 h (Fig. 2 A  and B) , and CYC 20 μM after 48 h (Fig. 2 B and C) .
A number of studies on structure-activity relationship (SAR) demonstrated that flavonoids can reverse MDR (Katayama et al., 2007; Kitagawa et al., 2005; Mohana et al., 2016) . In human leukemia K5 L2 cells transfected with human MDR1, BCRP, and MDP1 cDNAs, flavonoids selectively inhibited BCRP-mediated resistance to mitoxantrone and SN-38 (the active metabolite of irinotecan) (Katayama et al., 2007) . Therefore, we analyzed the function of commonly expressed efflux pumps, P-gp and BCRP, in MDA-MB-231 cells treated with rutin (20 or 50 μM) or commercially available pump inhibitors. As reported in Fig. 5 , rutin, at both doses tested, exhibited similar effects compared with inhibitors. These results also explain the different efficacy of rutin on poorly expressing efflux pump MCF-7 and overexpressing efflux pump MDA-MB-231 cells.
Moreover, in Katayama study, flavonols were the second most active inhibitors among the flavonoid classes, after the flavone group, and an SAR for BCRP inhibition by flavonoids was proposed as follows: (i) the double bond between position 2 and 3 of the C-ring are associated with high inhibitory activity against BCRP; (ii) the 4 0 -O-methoxylation of the B-ring or the 4 0 -hydroxylation of the B-ring are also associated with more potent BCRP inhibition; (iii) the 3-hydroxylation of the C-ring or the 3 0 -hydroxylation of the B-ring reduce BCRP inhibitory activity (Katayama et al., 2007) . Intriguingly, rutin possesses a double bond between positions 2 and 3 of the C-ring, a -OH group at 4 0 position of the B-ring, and 3 0 position of the B-ring is not substituted. Otherwise, in multidrug-resistant P-gp overexpressing KB-C2 cells (a human epidermal carcinoma cell line), quercetin overcame MDR and increased accumulation of daunorubicin more effectively than glycosides rutin and quercetin-3-O-glucoside (Kitagawa et al., 2005) . Very recently, molecular docking and quantitative SAR analyses were carried out for 40 phytochemicals in the drug-binding site of the transmembrane domain of P-gp (Mohana et al., 2016) . On the basis of this screening, selected flavonoids were tested for P-gp inhibition in P-gp overexpressing cell lines using calcein AM and rhodamine 123 efflux assays (Mohana et al., 2016) . In line with our results, quercetin and rutin were the most powerful P-gp inhibitors, and, at 10 μM, both flavonoids significantly reduced resistance to paclitaxel in cytotoxicity assay and decreased the expression level of P-gp protein (Mohana et al., 2016) .
Furthermore, rutin has been very recently investigated also as radiosensitizing agent in human colon adenocarcinoma HT-29 cells: rutin pre-treatment at 80 μM combined with 4 Gy radiation highly enhanced cytotoxicity by activating apoptosis (Vijay et al., 2016) . Downregulation of programmed cell death (PCD) is a pivotal phenomenon, as well as a mechanism of MDR. In particular, externalization of phosphatidylserine, that is, the movement of this phospholipid from the inner to the outer monolayer of plasma membrane, represents a biochemical feature of apoptosis. Indeed, under oxidative conditions, apoptotic cells are recognized and phagocytized by macrophages that express receptors for phosphatidylserine, in a caspase-related process (Balasubramanian et al., 2007) . In our experimental conditions, no statistically significant change in the number of MDA-MB-231 cells with Annexin+ and Caspase-3/7+ apoptotic phenotypes was observed, despite, at 48 h, rutin slightly triggered PCD, consistently with the arrest of cell cycle. This effect appears more evident in MCF-7, at all experimental times. Pan et al. (2012) showed that genistein (a flavonoid) strongly inhibited viability of MDA-MB-231 cells activating phosphatidylserine externalization and apoptosis. They also reported a cell cycle arrest at G2/M phase (Pan et al., 2012) , before a cell entries mitosis, in agreement with our results recorded 48 h after incubation with 20 μM rutin. Noteworthy, at this time point, we found 50 μM rutin inhibited cell cycle at G0/G1 phase. Due to its chemical structure, rutin can coordinate metals to form complexes, thus improving its biological activity. Indeed, combination of paclitaxel with rutin or rutin-Zn (II) exhibited the highest therapeutic efficacy by activating apoptosis and arresting cell cycle (Ne et al., 2015) . Both processes were also induced by rutin (50-100 μM) in human glioblastoma GL-15 cells (Santos et al., 2011) . Likewise, in the neuroblastoma cell line LAN-5, 50 and 100 μM rutin arrested cell cycle at the G2/M (Chen et al., 2013) . Intriguingly, after treatment with 50 μM rutin, Annexin+ phenotype was reported in approximately 11% of those cells (Chen et al., 2013) , in agreement with our results showing that, after 24-h incubation with 50 μM rutin, percentages of apoptotic cells (Annexin+) were approximately 15 and 18% for MDA-MB-231 and MCF-7 cells, respectively.
In a clinical perspective, we should mention as rutin as phytochemical is a xenobiotic; therefore, its therapeutic efficacy in humans greatly depends on the oral bioavailability, similarly to what occurs in the case of resveratrol (Varoni et al., 2016) . Intestinal absorption and metabolism of rutin have been demonstrated in Caco-2 (human epithelial colorectal adenocarcinoma) cells, an in vitro model of drug absorption, transport, and metabolism (Zhang et al., 2013) . A specific transport system for rutin was suggested, able to mediate its movement across the cell apical membrane, and approximately 33% of the flavonoid was metabolized to glucuronidated rutin (Zhang et al., 2013) . Importantly, after food intake, plasma rutin levels increased more than the quercetin ones in healthy volunteers (Simonetti et al., 2005) . Pharmacokinetic parameters of rutin have also been investigated in healthy subjects (Erlund et al., 2000) : after oral administration of rutin and its aglycone (quercetin), the mean area under the plasma concentration-time curve from 0 to 32 h [AUC ] and maximum plasma concentration (C max ) values resulted similar, though time to reach C max (t max ) was significantly shorter after the quercetin intake than after the rutin administration (Erlund et al., 2000) .
In conclusion, our results demonstrate that rutin reverses MDR in human breast cancer cells by overcoming the drug efflux from the cell by ABC transporters and promoting PCD with the arrest of cell cycle. These events impair the cancer cell machinery involved in drug-resistance development. In particular, rutin non-selectively counteracted P-gp and BCRP pumps, thus increasing sensitivity to CYC and MTX. Basing on these promising results, further preclinical investigations are urgent in order to verify the potential of rutin as adjuvant agent in cancer therapy.
